Abbott Laboratories (NYSE: ABT): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Stocks Info

ABT belongs to the Healthcare sector of the NYSE while operating in the Medical Devices industry. The current market capitalization of Abbott Laboratories is $176.82B. A total of 6.27 million shares were traded on the day, compared to an average of 5.64M shares.

In the most recent transaction, Funck, Jr. Robert E. sold 10,097 shares of ABT for 104.57 per share on May 10 ’24. After the transaction, the EXECUTIVE VICE PRESIDENT now owns 211,341 company shares. In a previous transaction on May 07 ’24, Earnhardt Lisa D sold 22,852 shares at 106.25 per share. ABT shares that EXECUTIVE VICE PRESIDENT owns now total 61,462.

Among the insiders who sold shares, Salvadori Daniel Gesua Sive disposed of 963 shares on Mar 01 ’24 at a per-share price of $118.50. This resulted in the EXECUTIVE VICE PRESIDENT holding 125,697 shares of ABT after the transaction. In another insider transaction, ALLEN HUBERT L sold 853 shares at $118.50 per share on Mar 01 ’24. Company shares held by the EXECUTIVE VICE PRESIDENT now total 184,806.

Dividend

Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Abbott Laboratories pays an annual dividend of $2.12, resulting in a dividend yield of 2.09%, and it has a price to earnings (P/E) ratio of 31.66. ABT’s most recent ex-dividend date was 7/15/2024 when it declared a $0.55 quarterly dividend that was paid in cash on 8/15/2024. Previously, the company paid the dividend on 5/15/2024 with an ex-dividend date of 4/12/2024. The ABT stock dividend was $0.55 per share in cash.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ABT has a high of $121.64 and a low of $89.67.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ABT’s latest balance sheet shows that the firm has $10.25B in Cash & Short Term Investments as of fiscal 2021. There were $19.01B in debt and $13.11B in liabilities at the time. Its Book Value Per Share was $22.31, while its Total Shareholder’s Equity was $36.02B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABT is Buy with a score of 4.50.

Most Popular

Related Posts